CN105579451B - 作为NIK抑制剂的新型1‑(4‑嘧啶基)‑1H‑吡咯并[3,2‑c]吡啶衍生物 - Google Patents

作为NIK抑制剂的新型1‑(4‑嘧啶基)‑1H‑吡咯并[3,2‑c]吡啶衍生物 Download PDF

Info

Publication number
CN105579451B
CN105579451B CN201480052786.XA CN201480052786A CN105579451B CN 105579451 B CN105579451 B CN 105579451B CN 201480052786 A CN201480052786 A CN 201480052786A CN 105579451 B CN105579451 B CN 105579451B
Authority
CN
China
Prior art keywords
alkyl
group
hydrogen
het
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480052786.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN105579451A (zh
Inventor
G.海恩德
P.蒂斯塞里
D.E.克拉克
J.J.库拉戈维斯基
C.马克勒奥德
S.E.马恩
T.A.潘查
S.C.普赖斯
J.G.蒙塔纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN105579451A publication Critical patent/CN105579451A/zh
Application granted granted Critical
Publication of CN105579451B publication Critical patent/CN105579451B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201480052786.XA 2013-09-26 2014-09-25 作为NIK抑制剂的新型1‑(4‑嘧啶基)‑1H‑吡咯并[3,2‑c]吡啶衍生物 Expired - Fee Related CN105579451B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP13186139 2013-09-26
EP13186139.5 2013-09-26
EP14176121.3 2014-07-08
EP14176121 2014-07-08
PCT/EP2014/070484 WO2015044267A1 (en) 2013-09-26 2014-09-25 NEW 1-(4-PYRIMIDINYL)-1H-PYRROLO[3,2-c]PYRIDINE DERIVATIVES AS NIK INHIBITORS

Publications (2)

Publication Number Publication Date
CN105579451A CN105579451A (zh) 2016-05-11
CN105579451B true CN105579451B (zh) 2017-10-27

Family

ID=51619194

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480052786.XA Expired - Fee Related CN105579451B (zh) 2013-09-26 2014-09-25 作为NIK抑制剂的新型1‑(4‑嘧啶基)‑1H‑吡咯并[3,2‑c]吡啶衍生物

Country Status (14)

Country Link
US (1) US10005773B2 (enExample)
EP (1) EP3071566B1 (enExample)
JP (1) JP6402179B2 (enExample)
KR (1) KR102317334B1 (enExample)
CN (1) CN105579451B (enExample)
AU (1) AU2014327233B2 (enExample)
BR (1) BR112016005914A2 (enExample)
CA (1) CA2922753C (enExample)
EA (1) EA029595B1 (enExample)
ES (1) ES2804595T3 (enExample)
IL (1) IL244706B (enExample)
MX (1) MX373186B (enExample)
TW (1) TWI704146B (enExample)
WO (1) WO2015044267A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI663166B (zh) 2013-04-24 2019-06-21 健生藥品公司 新化合物
TWI704146B (zh) 2013-09-26 2020-09-11 比利時商健生藥品公司 用作ＮＩＫ抑制劑之新的1-(４-嘧啶基)-１Ｈ-吡唑並[３,２-ｃ]吡啶衍生物
TWI627173B (zh) 2013-09-26 2018-06-21 比利時商健生藥品公司 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物
EP3209654B1 (en) 2014-10-23 2018-10-03 Janssen Pharmaceutica N.V. New pyrazole derivatives as nik inhibitors
EA033237B1 (ru) 2014-10-23 2019-09-30 Янссен Фармацевтика Нв Новые производные пиразолопиримидина в качестве ингибиторов nik, фармацевтическая композиция и лекарственное средство, содержащее ее
KR102524622B1 (ko) 2014-10-23 2023-04-20 얀센 파마슈티카 엔.브이. Ｎｉｋ 억제제로서의 신규 티에노피리미딘 유도체
ES2718557T3 (es) 2014-10-23 2019-07-02 Janssen Pharmaceutica Nv Nuevos compuestos como inhibidores de nik
WO2017125534A1 (en) 2016-01-22 2017-07-27 Janssen Pharmaceutica Nv New 6-membered heteroaromatic substituted cyanoindoline derivatives as nik inhibitors
JP6910359B2 (ja) 2016-01-22 2021-07-28 ヤンセン ファーマシューティカ エヌ．ベー． Ｎｉｋ阻害剤としての新たな置換されたシアノインドリン誘導体
JP6936815B2 (ja) * 2016-06-30 2021-09-22 ヤンセン ファーマシューティカ エヌ．ベー． Ｎｉｋ阻害剤としてのヘテロ芳香族誘導体
AU2017289317B2 (en) * 2016-06-30 2021-04-01 Janssen Pharmaceutica Nv Cyanoindoline derivatives as NIK inhibitors
WO2018037058A1 (en) 2016-08-24 2018-03-01 F. Hoffmann-La Roche Ag 2-azabicyclo[3.1.0]hexan-3-one derivatives and methods of use
CN109641894B (zh) 2016-08-24 2022-09-09 豪夫迈·罗氏有限公司 2-氮杂双环[3.1.0]己烷-3-酮衍生物及使用方法
FI3976597T3 (fi) 2019-05-31 2024-09-25 Janssen Pharmaceutica Nv Nf-kb:tä indusoivan kinaasin pienimolekyylisiä estäjiä
CN113816957B (zh) * 2021-10-29 2023-04-07 浙江工业大学 4-(7-氮杂吲哚)-2-氨基嘧啶类化合物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007058850A2 (en) * 2005-11-10 2007-05-24 Smithkline Beecham Corporation Inhibitors of akt activity
WO2009158011A1 (en) * 2008-06-26 2009-12-30 Amgen Inc. Alkynyl alcohols as kinase inhibitors
WO2010042337A1 (en) * 2008-10-07 2010-04-15 Merck Sharp & Dohme Corp. Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3990061B2 (ja) * 1998-01-05 2007-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 プリン誘導体および糖尿病の予防・治療剤としてのアデノシンａ２受容体拮抗剤
MXPA06012449A (es) 2004-04-26 2007-01-17 Pfizer Inhibidores de la enzima integrasa de vih.
DE102008005493A1 (de) 2008-01-22 2009-07-23 Merck Patent Gmbh 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate
EP2320895A2 (en) 2008-07-03 2011-05-18 Exelixis, Inc. Cdk modulators
CN101723936B (zh) 2008-10-27 2014-01-15 上海睿星基因技术有限公司 激酶抑制剂及其在药学中的用途
WO2011050245A1 (en) * 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
KR20130133051A (ko) 2011-03-16 2013-12-05 에프. 호프만-라 로슈 아게 6,5-헤테로사이클릭 프로파길릭 알콜 화합물 및 이의 용도
TWI663166B (zh) * 2013-04-24 2019-06-21 健生藥品公司 新化合物
TWI704146B (zh) 2013-09-26 2020-09-11 比利時商健生藥品公司 用作ＮＩＫ抑制劑之新的1-(４-嘧啶基)-１Ｈ-吡唑並[３,２-ｃ]吡啶衍生物
TWI627173B (zh) * 2013-09-26 2018-06-21 比利時商健生藥品公司 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物
ES2718557T3 (es) 2014-10-23 2019-07-02 Janssen Pharmaceutica Nv Nuevos compuestos como inhibidores de nik
EP3209654B1 (en) 2014-10-23 2018-10-03 Janssen Pharmaceutica N.V. New pyrazole derivatives as nik inhibitors
EA033237B1 (ru) 2014-10-23 2019-09-30 Янссен Фармацевтика Нв Новые производные пиразолопиримидина в качестве ингибиторов nik, фармацевтическая композиция и лекарственное средство, содержащее ее
KR102524622B1 (ko) 2014-10-23 2023-04-20 얀센 파마슈티카 엔.브이. Ｎｉｋ 억제제로서의 신규 티에노피리미딘 유도체

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007058850A2 (en) * 2005-11-10 2007-05-24 Smithkline Beecham Corporation Inhibitors of akt activity
WO2009158011A1 (en) * 2008-06-26 2009-12-30 Amgen Inc. Alkynyl alcohols as kinase inhibitors
WO2010042337A1 (en) * 2008-10-07 2010-04-15 Merck Sharp & Dohme Corp. Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity

Also Published As

Publication number Publication date
IL244706B (en) 2021-02-28
AU2014327233A1 (en) 2016-03-10
KR102317334B1 (ko) 2021-10-26
JP6402179B2 (ja) 2018-10-10
KR20160058814A (ko) 2016-05-25
US10005773B2 (en) 2018-06-26
MX373186B (es) 2020-05-12
TWI704146B (zh) 2020-09-11
AU2014327233B2 (en) 2018-03-01
JP2016531868A (ja) 2016-10-13
TW201602104A (zh) 2016-01-16
CA2922753A1 (en) 2015-04-02
US20160257679A1 (en) 2016-09-08
EP3071566A1 (en) 2016-09-28
CN105579451A (zh) 2016-05-11
HK1224295A1 (zh) 2017-08-18
CA2922753C (en) 2021-08-17
EA029595B1 (ru) 2018-04-30
BR112016005914A2 (pt) 2017-08-01
MX2016003861A (es) 2016-07-26
EP3071566B1 (en) 2020-04-15
ES2804595T3 (es) 2021-02-08
IL244706A0 (en) 2016-04-21
WO2015044267A1 (en) 2015-04-02
EA201690645A1 (ru) 2016-08-31

Similar Documents

Publication Publication Date Title
CN105579451B (zh) 作为NIK抑制剂的新型1‑(4‑嘧啶基)‑1H‑吡咯并[3,2‑c]吡啶衍生物
CN105579452B (zh) 作为NIK抑制剂的新型3‑(1H‑吡唑‑4‑基)‑1H‑吡咯并[2,3‑c]吡啶衍生物
TWI663166B (zh) 新化合物
CN107074882B (zh) 作为nik抑制剂的新的吡唑并嘧啶衍生物
CN107074855B (zh) 作为nik抑制剂的新的化合物
CN107074818B (zh) 作为nik抑制剂的吡唑衍生物
CN107074881B (zh) 作为nik抑制剂的新的噻吩并嘧啶衍生物
HK1224295B (en) New 1-(4-pyrimidinyl)-1 h-pyrrolo(3,2-c) pyridine derivatives as nik inhibitors
HK1224664A1 (en) New 3-(1h-pyrazol-4-yl)-1h-pyrrolo(2,3-c) pyridine derivatives as nik inhibitors
HK1224664B (en) New 3-(1h-pyrazol-4-yl)-1h-pyrrolo(2,3-c) pyridine derivatives as nik inhibitors
HK1215430B (zh) 3-(2-氨基嘧啶-4-基)-5-(3-羟丙炔基)-1h-吡咯并[2，3-c]吡啶衍生物作爲nik抑制剂用於治疗癌症

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1224295

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1224295

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20171027